Effect of medication therapy management on discharged patient with Ulcerative Colitis with initial stage biotherapy: a randomized study

Main Article Content

Qinbo Wang
Yuan Zhou
Guozeng Ye
Yingjuan Ou
Lihong Huang
Wenfeng Liu
Xiaoyan Li
Xia Wu


Ulcerative Colitis (UC), Medication therapy management (MTM), first-stage, biotherapy, adherence


Purpose: The aim of this study was to explore the effects of medication therapy management in improving perception, medication adherence, and disease control in UC patients with first-stage of biotherapy. Subjects and Methods: A total of 120 patients with UC who received first-stage biotherapy participated in this study. The patients were divided into MTM group and CFU group. Both groups received three times follow-up, which were carried out at first, third, and sixth discharged month, Group A was followed with the MTM method, and Group B received conventional follow-up. MDRKT was used to assess patient perception, adherence to treatment was assessed by MMSA-8, and we also explored disease control and patient satisfaction. Results: A total of 116 patients completed the survey, the  MTM group showed a significant improvement in perception, 84.2% of patients can correctly handle ADEs and 82.5% of patients knew what to do when they leak medication, 87.8% of patients in the MTM group had better adherence than 71.2% in the CPU group (P<0.05). The evaluation of disease control showed that 56.1% of patients in the Group A were in remission which was significantly higher than 32.2% in the Group B (P<0.05). Furthermore, the result of the questionnaire survey showed that perception, ADE, self-management, anxiety, and satisfaction were better in the MTM group than in the CPU group (P<0.05). Conclusion: The MTM group was effective in improving medication adherence, perception, and satisfaction in the patient with ulcerative colitis treated with first-stage biotherapy, and the disease control significantly improved.

Abstract 851 | PDF Downloads 166


1. Feuerstein JD, Moss AC, Farraye FA. Ulcerative Colitis. Mayo Clin Proc. 2019;94(7):1357-1373. https://doi.org/10.1016/j. mayocp.2019.01.018.
2. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2(4947):1041-8. https:// doi.org/10.1136/bmj.2.4947.1041
3. Ko CW, Singh S, Feuerstein JD, et al.American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2019;156(3):748- 764. https://doi.org/10.1053/j.gastro.2018.12.009
4. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. https://doi.org/10.1016/S0140- 6736(16)32126-2
5. Tripathi K, Dong J, Mishkin BF, et al. Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. Clin Exp Gastroenterol. 2021;14:343-351. https://doi.org/10.2147/CEG.S237653
6. Naeck-Boolauky P, Adio J, Burch J. Review of normal gastrointestinal tract, ulcerative colitis, proctitis and rectal medication adherence. Br J Nurs. 2020;29(14):805-811. https://doi.org/10.12968/bjon.2020.29.14.805
7. Forster AJ, Murff HJ, Peterson JF, et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161-7. https://doi.org/10.7326/0003-4819-138-3-200302040-00007
8. Coleman EA, Smith JD, Raha D, et al. Posthospital medication discrepancies: prevalence and contributing factors. Arch Intern Med. 2005;165(16):1842-7. https://doi.org/10.1001/archinte.165.16.1842
9. Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76-87. https://doi.org/10.1001/jamainternmed.2014.5841
10. Chui MA, Mott DA, Maxwell L. A qualitative assessment of a community pharmacy cognitive pharmaceutical services program, using a work system approach. Res Social Adm Pharm. 2012;8(3):206-16. https://doi.org/10.1016/j.sapharm.2011.06.001
11. Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017;112(2):241-258. https://doi.org/10.1038/ajg.2016.537
12. Geraghty EM, Franks P, Kravitz RL. Primary care visit length, quality, and satisfaction for standardized patients with depression. J Gen Intern Med. 2007;22(12):1641-7. https://doi.org/10.1007/s11606-007-0371-5
13. Gernant SA, Nguyen MO, Siddiqui S, et al. Use of pharmacy technicians in elements of medication therapy management delivery: A systematic review. Res Social Adm Pharm. 2018;14(10):883-890. https://doi.org/10.1016/j.sapharm.2017.11.012
14. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296(21):2563-71. https://doi.org/10.1001/
15. Hedegaard U, Kjeldsen LJ, Pottegård A, et al. Improving Medication Adherence in Patients with Hypertension: A Randomized Trial. Am J Med. 2015;128(12):1351-61. https://doi.org/10.1016/j.amjmed.2015.08.011
16. Cooper JM, Collier J, James V, et al. Beliefs about personal control and self-management in 30-40 year olds living with Inflammatory Bowel Disease: a qualitative study. Int J Nurs Stud. 2010;47(12):1500-9. https://doi.org/10.1016/j.ijnurstu.2010.05.008
17. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317(26):1625-9. https://doi.org/10.1056/NEJM198712243172603
18. Hindryckx P, Jairath V, D’Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13(11):654-664. https://doi.org/10.1038/nrgastro.2016.116
19. Iglesias-Rey M, Barreiro-de Acosta M, Caamaño-Isorna F, et al. Psychological factors are associated with changes in the health- related quality of life in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20(1):92-102. https://doi.org/10.1097/01. MIB.0000436955.78220.bc
20. Kucharzik T, Koletzko S, Kannengiesser K, et al. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Dtsch Arztebl Int. 2020;117(33-34):564-574. https://doi.org/10.3238/arztebl.2020.0564
21. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54.e42. https://doi.org/10.1053/j.gastro.2011.10.001
22. Ou Q, Wang L, Wang K, et al. Effect of probiotics supplementation combined with WeChat platform health management on nutritional status, inflammatory factors, and quality of life in patients with mild-to-moderate ulcerative colitis: a randomized trial. Ann Palliat Med. 2021;10(6):6606-6616. https://doi.org/10.21037/apm-21-1056
23. Ogedegbe G, Tobin JN, Fernandez S, et al. Counseling African Americans to Control Hypertension: cluster-randomized clinical trial main effects. Circulation. 2014;129(20):2044-51. https://doi.org/10.1161/CIRCULATIONAHA.113.006650
24. Pennock D, Barbour L, Green R, et al. A medication therapy management residency rotation adjusts to coronavirus disease 2019 constraints. J Am Pharm Assoc (2003). 2021;61(4S):S7-S11. https://doi.org/10.1016/j.japh.2021.01.024
25. Panahiazar M, Taslimitehrani V, Jadhav A, et al. Empowering Personalized Medicine with Big Data and Semantic Web Technology: Promises, Challenges, and Use Cases. Proc IEEE Int Conf Big Data. 2014;2014:790-795. https://doi.org/10.1016/j. japh.2021.01.024 10.1109/BigData.2014.7004307
26. Marcasciano M, Kaciulyte J, Mori FLR, et al. Breast surgeons updating on the thresholds of COVID-19 era: results of a multicenter collaborative study evaluating the role of online videos and multimedia sources on breast surgeons education and training. Eur Rev Med Pharmacol Sci. 2020;24(14):7845-7854. https://doi.org/10.1016/j.japh.2021.01.024 10.26355/ eurrev_202007_22289
27. Basheti IA, Al-Qudah RA, Obeidat NM, et al. Home medication management review in outpatients with chronic diseases in Jordan: a randomized control trial. Int J Clin Pharm. 2016;38(2):404-13. https://doi.org/10.1016/j.japh.2021.01.024 10.1007/ s11096-016-0266-9

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>